Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation via machine learning

EIDD-2801 is an orally bioavailable prodrug, which will be applied for emergency use authorization from the U.S. Food and Drug Administration for the treatment of COVID-19. To investigate the optimal parameters, EIDD-2801 was optimized via a four-step synthesis with high purity of 99.9%. The hydroxy...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Zhen, Dong, Bin, Wang, Renbing, Huang, Dechun, Wang, Jubo, Feng, Xi, Bian, Jinlei, Li, Zhiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529884/
https://www.ncbi.nlm.nih.gov/pubmed/34703727
http://dx.doi.org/10.1016/j.apsb.2021.10.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529884/
https://www.ncbi.nlm.nih.gov/pubmed/34703727
http://dx.doi.org/10.1016/j.apsb.2021.10.011

Ejemplares similares